Proscia, founded in 2014, is a digital pathology company headquartered and operating worldwide. Its core product is Concentriq, an AI-native platform designed to support pathology workflows in cancer discovery and diagnosis. The platform brings artificial intelligence capabilities to pathology experts working in both clinical and research settings.
The company's technology is deployed at significant scale. Concentriq powers over 12 million cases annually across more than 4,000 hospitals and clinics worldwide. Its adoption extends deep into the pharmaceutical industry as well, with 16 of the top 20 pharmaceutical companies running on the platform.
Proscia's technical work sits at the intersection of AI, precision medicine, and healthcare. The team includes engineers, scientists, and healthcare innovators tackling problems in computational pathology. The company operates within the healthcare, pharmaceuticals, and pathology verticals, serving both enterprise pharmaceutical customers and clinical institutions.
